KR960703545A - 테스토스테론의 공급을 위한 피부패치 및 방법(skin patches and methods for providing testosterone) - Google Patents

테스토스테론의 공급을 위한 피부패치 및 방법(skin patches and methods for providing testosterone) Download PDF

Info

Publication number
KR960703545A
KR960703545A KR1019960700568A KR19960700568A KR960703545A KR 960703545 A KR960703545 A KR 960703545A KR 1019960700568 A KR1019960700568 A KR 1019960700568A KR 19960700568 A KR19960700568 A KR 19960700568A KR 960703545 A KR960703545 A KR 960703545A
Authority
KR
South Korea
Prior art keywords
testosterone
estrogen
woman
amount
therapy
Prior art date
Application number
KR1019960700568A
Other languages
English (en)
Other versions
KR0180030B1 (ko
Inventor
디. 에버트 찰즈
파텔 다인스 시
알란 메이저 노만
벤카테쉬와란 스리니바산
Original Assignee
디. 에버트 찰즈
테라테크 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960703545(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 디. 에버트 찰즈, 테라테크 인코퍼레이티드 filed Critical 디. 에버트 찰즈
Publication of KR960703545A publication Critical patent/KR960703545A/ko
Application granted granted Critical
Publication of KR0180030B1 publication Critical patent/KR0180030B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

테스토스테론 대체 요법을 필요로 하는 여성에게 그러한 치료를 제공하는 방법으로서, 이 방법은 상기 여성의 피부에 그 여성에게 50 내지 500㎍/일의 테스토스테론을 경피적으로 전달하는 테스토스테론-전달 패치를 부착하는 것으로 이루어진다.

Description

테스토스테론의 공급을 위한 피부패치 및 방법(SKIN PATCHES AND METHODS FOR PROVIDING TESTOSTERONE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
도면은 본 발명 실시예 2에 기술된 데이타의 그래프이다.

Claims (8)

  1. 테스토스테론 대체요법이 필요한 여성에게 그러한 요법을 제공하는 방법으로서, 건강한 젊은 성인 여성에서의 테스토스테론의 내생적 혈중 레벨과 실질적으로 일치하는 여성에서의 테스토스테론의 혈중 레벨을 제공하는 양으로 여성에게 경피적으로 테스토스테론을 투약하는 것으로 이루어진 제공방법.
  2. 제1항에 있어서, 상기 양이 50 내지 500㎍/일의 범위내인 것을 특징으로 하는 제공방법.
  3. 테스토스테론 대체요법이 필요한 여성에게 경피적으로 그러한 요법을 제공하기 위한 피부패치로서, (a) 받침(backing)층과, (b) 상기 요법을 제공하기에 충분한 1일 투여량의 테스토스테론을 제공하는, 중합체 담체중의 테스토스테론의 용액으로 이루어진 기질(matrix)층의 적층된 조성물로 이루어진 피부패치.
  4. 제3항에 있어서, 중합체 담체는 압력 감응 접착제이고 패치는 50 내지 500㎍ 테스토스테론/일을 제공하는 것을 특징으로 하는 피부패치.
  5. 복합 테스토스테론 및 에스트로겐 대체요법이 필요한 여성에게 그러한 요법을 제공하는 방법으로서, 건강한 젊은 성인 여성에서의 테스토스테론 및 에스트로겐의 내생적 혈중 레벨과 실질적으로 일치하는 여성에서의 테스토스테론 및 에스트로겐의 혈중 레벨을 제공하는 각각의 양으로 여성에게 경피적으로 테스토스테론 및 에스트로겐을 공투약하는 것으로 이루어진 제공방법.
  6. 제5항에 있어서, 테스토스테론의 양은 50 내지 500㎍/일이고 에스트로겐은 17-에스트라디올이고 에스트로겐의 양은 25 내지 200㎍/일인 것을 특징으로 하는 제공방법.
  7. 테스토스테론 및 에스트로겐 대체요법이 필요한 여성에게 경피적으로 그러한 요법을 제공하기 위한 피부패치로서, (a) 받침층과, (b) 여성의 피부와 확산연통되도록 하고 여성의 피부를 통해 치료적으로 효과적 양의 테스토스테론 및 에스트로겐을 전달하도록 적합시킨 테스토스테론-및-에스트로겐-함유 저장층으로 이루어진 피부패치.
  8. 제7항에 있어서, 테스토스테론의 양은 50 내지 500㎍/일이고 에스트로겐은 17-에스트라디올이고 에스트로겐의 양은 25 내지 200㎍/일인 것을 특징으로 하는 피부패치.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700568A 1993-08-03 1994-07-27 테스토스테론의 공급을 위한 피부패치 및 방법 KR0180030B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08099923 US5460820B1 (en) 1993-08-03 1993-08-03 Method for providing testosterone and optionally estrogen replacement therapy to women
US8/099,923 1993-08-03
US08/099,923 1993-08-03
PCT/US1994/008637 WO1995003764A1 (en) 1993-08-03 1994-07-27 Skin patches and methods for providing testosterone

Publications (2)

Publication Number Publication Date
KR960703545A true KR960703545A (ko) 1996-08-31
KR0180030B1 KR0180030B1 (ko) 1999-04-01

Family

ID=22277259

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700568A KR0180030B1 (ko) 1993-08-03 1994-07-27 테스토스테론의 공급을 위한 피부패치 및 방법

Country Status (17)

Country Link
US (1) US5460820B1 (ko)
EP (2) EP0712303B2 (ko)
JP (4) JPH09500653A (ko)
KR (1) KR0180030B1 (ko)
CN (2) CN1142753C (ko)
AT (1) ATE304845T1 (ko)
AU (1) AU690578B2 (ko)
CA (1) CA2168879C (ko)
DE (2) DE69434491T3 (ko)
DK (1) DK0712303T4 (ko)
ES (1) ES2245777T5 (ko)
LU (1) LU91309I2 (ko)
NL (1) NL300259I2 (ko)
NO (1) NO316844B1 (ko)
TW (1) TW492881B (ko)
WO (1) WO1995003764A1 (ko)
ZA (1) ZA945782B (ko)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AU2746397A (en) * 1996-04-30 1997-11-19 Theratech, Inc. Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers
US6228852B1 (en) 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
DE19646050A1 (de) * 1996-11-08 1998-05-14 Labtec Gmbh Transdermales System mit einem speziellen Süßstoff zur Erhöhung der transdermalen Bioverfügbarkeit
US5951999A (en) 1997-02-21 1999-09-14 Adhesives Research, Inc. Transdermal pressure sensitive adhesive drug delivery system
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
EP0979072B1 (en) * 1997-02-28 2005-04-27 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of testosterone
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US6692763B1 (en) 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
WO2000024377A1 (en) * 1998-10-23 2000-05-04 Idea Innovative Dermale Applikationen Gmbh Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
DK1031347T3 (da) 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
AU2004222794B2 (en) * 1999-06-11 2007-03-08 Watson Pharmaceuticals, Inc. Non-oral androgenic steroids for women
MXPA01012769A (es) * 1999-06-11 2003-06-24 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales para mujeres.
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
CA2389865A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
US6896898B1 (en) 1999-11-19 2005-05-24 Xel Herbaceuticals, Inc. Transdermal delivery system for alkaloids of aconitum species
US20050042271A1 (en) * 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
KR100403051B1 (ko) * 2000-07-25 2003-10-23 일양약품주식회사 음낭 외 피부에 적용가능한 남성호르몬 경피흡수 패취제
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20030191096A1 (en) * 2002-04-03 2003-10-09 Leonard Thomas W. Method of hormonal therapy
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
US20080015170A1 (en) * 2005-12-01 2008-01-17 The Procter & Gamble Company Method of treating menopausal women transdermally with testosterone
EP1839705A1 (en) 2006-03-27 2007-10-03 Universidad de Alcala Transcutaneous laser therapy patch
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022487A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
EP2506838A1 (en) * 2009-12-01 2012-10-10 Noven Pharmaceuticals, INC. Transdermal testosterone device and delivery
CN103930437A (zh) 2011-03-16 2014-07-16 安姆根有限公司 Nav1.3和Nav1.7的强效及选择性抑制剂
CN102772417B (zh) * 2012-07-24 2014-01-29 上海现代药物制剂工程研究中心有限公司 包载睾酮的自黏性弹性体基质的周效经皮贴剂及制法
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
US9452174B2 (en) 2014-08-20 2016-09-27 Professional Compounding Centers Of America Oral transmucosal pharmaceutical compositions including testosterone and a C-SERM
PT109445B (pt) 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
AU2019299538A1 (en) * 2018-07-05 2021-01-28 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
CA2065311C (en) † 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
DE4210165A1 (de) † 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme

Also Published As

Publication number Publication date
EP0712303A4 (en) 1997-04-23
NL300259I1 (nl) 2007-04-02
LU91309I2 (fr) 2007-06-15
DE69434491T2 (de) 2006-06-22
TW492881B (en) 2002-07-01
AU7517894A (en) 1995-02-28
JP2002121136A (ja) 2002-04-23
NO960445D0 (no) 1996-02-02
CN1131907A (zh) 1996-09-25
EP0712303B2 (en) 2008-09-17
DK0712303T3 (da) 2006-01-16
EP0712303B1 (en) 2005-09-21
CA2168879A1 (en) 1995-02-09
AU690578B2 (en) 1998-04-30
EP1604651A1 (en) 2005-12-14
NL300259I2 (nl) 2007-09-03
NO960445L (no) 1996-03-26
CN1550233A (zh) 2004-12-01
CN1142753C (zh) 2004-03-24
WO1995003764A1 (en) 1995-02-09
ES2245777T5 (es) 2009-03-01
ATE304845T1 (de) 2005-10-15
NO316844B1 (no) 2004-06-01
CA2168879C (en) 2007-03-27
JP2005263814A (ja) 2005-09-29
JPH09500653A (ja) 1997-01-21
JP2009185074A (ja) 2009-08-20
DE69434491D1 (de) 2006-02-02
US5460820B1 (en) 1999-08-03
DE69434491T3 (de) 2009-04-30
DK0712303T4 (da) 2009-01-26
DE122007000006I1 (de) 2007-04-19
ES2245777T3 (es) 2006-01-16
EP0712303A1 (en) 1996-05-22
ZA945782B (en) 1995-03-10
KR0180030B1 (ko) 1999-04-01
US5460820A (en) 1995-10-24

Similar Documents

Publication Publication Date Title
KR960703545A (ko) 테스토스테론의 공급을 위한 피부패치 및 방법(skin patches and methods for providing testosterone)
AU760588B2 (en) Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
US4822617A (en) Drug delivery device
US5641504A (en) Skin permeation enhancer compositions using glycerol monolinoleate
NZ316026A (en) A transdermal therapeutic system (a hormone patch) in which drugs are contained which are released into the skin comprising a backing film and a pressure sensitive adhesive
HUP9802326A2 (hu) 17-Dezacetil-norgesztimát vagy valamely ösztrogénnel kombinált hatóanyag bevitelére alkalmas transzdermális készítmény
SI1009393T1 (en) Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience
KR900005969A (ko) 게스토덴을 함유하는 경피 투여용 제제
JPS62167724A (ja) 経皮性薬物投与テバイス
ATE238778T1 (de) Transdermales therapeutisches system zur abgabe von hormonen
ATE264098T1 (de) Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen
HU204203B (en) Plaster containing active ingredient which feeding the active ingredient into skin in controlled manner
AU2003215657A1 (en) Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
NZ332746A (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease
JPH09509948A (ja) タモキシフェン誘導体を含むパッチ形態の経皮系
EP0282156B1 (en) Composition for the prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
NZ509215A (en) Transdermal plaster preparation containing at least one active ingredient which influences blood serum lipid levels
EP1229909B1 (en) Transdermal delivery of lasofoxifene
US5077054A (en) Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
JP2002284701A (ja) ざ瘡の局所治療用パッチ
DE69530832D1 (de) Transdermales abgabesystem, das ein östrogen enthält
US5286491A (en) Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
YU71293A (sh) Transdermalni terapijski sistem za davanje fizostigmina na koži i postupak za njegovu izradu
BR9912688A (pt) Emplastro contendo estradiol para aplicaçãotransdérmica de hormÈnios

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20071126

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee